Portola Pharmaceuticals Inc  

(Public, NASDAQ:PTLA)   Watch this stock  
Find more results forPTLA
-0.01 (-0.02%)
After Hours: 49.96 0.00 (0.00%)
Nov 27, 1:24p.m. GMT-5  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 49.82 - 50.43
52 week 26.26 - 57.96
Open 49.95
Vol / Avg. 433,203.00/512,750.00
Mkt cap 2,633.17M
P/E     -
Div/yield     -
EPS -3.93
Shares 52.71M
Beta     -
Inst. own 98%
Nov 19, 2015
Portola Pharmaceuticals Inc Analyst and Investor Day - Webcast
Nov 11, 2015
Portola Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 9, 2015
Q3 2015 Portola Pharmaceuticals Inc Earnings Call - Webcast
Nov 9, 2015
Q3 2015 Portola Pharmaceuticals Inc Earnings Release
Sep 17, 2015
Portola Pharmaceuticals Inc at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -1894.16% -1424.67%
Operating margin -1908.10% -1429.26%
EBITD margin - -1413.24%
Return on average assets -52.87% -36.95%
Return on average equity -64.04% -42.58%
Employees 99 -
CDP Score - -


270 East Grand Avenue, Suite 22
United States - Map
+1-650-2446864 (Phone)
+1-650-2467376 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company has a program of selective Syk inhibitors, which is partnered with Biogen Idec Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa. Andexanet alfa is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor. Cerdulatinib is an orally available, potent dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.

Officers and directors

Charles J. Homcy M.D. Co-Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Hollings C. Renton III Independent Co-Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
William Lis Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Mardi C. Dier Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
John T. Curnutte M.D. Ph.D. Executive Vice President - Research & Development
Age: 63
Bio & Compensation  - Reuters
Tao Fu Executive Vice President, Chief Commercial and Business officer
Bio & Compensation  - Reuters
Laura A. Brege Director
Age: 57
Bio & Compensation  - Reuters
Dennis M. Fenton Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
John H. Johnson Director
Age: 57
Bio & Compensation  - Reuters
David C. Stump M.D. Director
Age: 65
Bio & Compensation  - Reuters